Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

scientific article published on 05 June 2018

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/BJH.15421
P932PMC publication ID6120509
P698PubMed publication ID29873072

P50authorStephan StilgenbauerQ47158807
Peter HillmenQ48086375
Constantine S. TamQ55445006
William G WierdaQ64026278
John C. ByrdQ66429603
Susan M O'BrienQ87633434
Jeffrey A JonesQ87803317
Anthony MatoQ89004907
Nyla A HeeremaQ89317565
Danelle F JamesQ92176351
Cathy ZhouQ104795915
Steven CoutreQ114290920
Alvina D ChuQ114341057
Fong ClowQ114341062
P2093author name stringAnders Osterborg
Richard R Furman
Karl Eckert
P2860cites workUblituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trialQ37633475
How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?Q38340201
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studyQ38956893
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trialQ39005118
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.Q40474461
Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic LeukemiaQ41848521
Survival of Del17p CLL Depends on Genomic Complexity and Somatic MutationQ42208521
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemiaQ46913558
Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis.Q46916349
Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalitiesQ68535307
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesQ24616084
TP53 mutation and survival in chronic lymphocytic leukemiaQ27851577
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinibQ27853011
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaQ29620690
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia GroupQ31097476
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialQ33412064
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialQ33419580
Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.Q33638819
Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patientsQ33821990
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemiaQ34008593
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaQ34052075
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialQ34141305
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 studyQ34240404
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemiaQ35407650
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibQ35450520
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaQ35903984
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic LeukemiaQ35958056
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimensQ36900364
Risk categories and refractory CLL in the era of chemoimmunotherapyQ37141887
P433issue4
P921main subjectibrutinibQ5984881
P304page(s)504-512
P577publication date2018-06-05
P1433published inBritish Journal of HaematologyQ4970200
P1476titleEvaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
P478volume182

Reverse relations

cites work (P2860)
Q91666607Chronic lymphocytic leukaemia: from genetics to treatment
Q89694000Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma
Q64092443First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
Q93040664Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
Q89600801Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry
Q92169106Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations

Search more.